Insights

345 Park Avenue South

Xchange Challenge

All floors are lab-ready and cabled for digital health.

Community

Residents

Leadership

Staff

Neighborhood

Be part of *Cure.*

Orange

Where scientists, entrepreneurs and visionaries converge.

Campus

Ecosystem

Event Spaces

Gallery

Networking hub

Space Availability

A place to *Succeed.*

Green

Joe Wilson How Life Sciences Companies Use AI to Target Investors Mega Menu Image 

Critical Discussions Advancing Healthcare

Events

Event Inquiry

Past Events

Speakers

Tuesday Talks

Cure *Events.*

Magenta

Cure Clips

Tuesday Talks Series

Cure *Tuesday Talks*

Award Finalists to be announced soon!

Partnerships and Sponsorships

Women in Science

XSeed Award

Connect with *Opportunity.*

Blue

Network

Cure Insights Article A Bionic Pancreas that will Help Parents Sleep More Peacefully image for Cure Insights Mega Menu.  Image credit Cottonbro Studio.

A Bionic Pancreas that will Help Parents Sleep More Peacefully

In-depth *Insights.*

About

Contact us

Albert Vanderlaan, JD, is involved in a broad range of corporate legal engagements for high growth technology companies, including IPOs, follow-on public offerings, private and public company securities law compliance matters, public company disclosure obligations, de-SPAC transactions, SPAC IPOs, venture financings and mergers and acquisitions. He also regularly advises public and private companies and their boards of directors on corporate governance issues.

Vanderlaan's clients include public and private companies in technology, automotive, Internet-related industries, real estate, finance and life sciences. He also represents underwriters in initial public offerings, follow-on offerings and PIPE offerings and venture capital firms in a variety of investment transactions.

Vanderlaan was named to the Deal’s Top Rising Stars 2021 list, which recognizes top new partners at U.S. law firms. Prior to joining Orrick, he was an attorney with Gunderson Dettmer and Cooley.

Partner at Orrick, Herrington & Sutcliffe LLP

Join us at Cure on January 31 to hear from experts about prospects for exits in the coming year, and how to strategize what flavor of exit would be right for your company—an IPO, M&A, JV, or something else.

Will IPOs Return in 2024?